


European Lead Factory– making a pan-European compound collection & screening centre a reality

Dimitrios Tzalis (Taros), Head of Chemistry

6th FIP Pharmaceutical Sciences World Congress 2017, Stockholm, Sweden 23 May 2017




















Interactions & Impact














The EU Lead Factory Model

Researcher










The EU Lead Factory Model

Researcher

in the lead







Hitting the Targets – and beyond!

Project Objectives

- Produce the best **200 000 screening compounds** in just 5 years
- Use **expertise and infrastructure** to boost innovation in early drug discovery in Europe
- Leverage combination of knowledge, strengths, capabilities and assets in academia, SMEs & big pharma in Europe
- \Rightarrow Building a factory
 - Defining best practice and governance
 - Set up an IT infrastructure





Best practice and governance

- Criteria and workflow for library/target proposal review/selection
- Library/target Selection Committee
- Criteria and workflow for library/target proposal validation
- Library/target Validation Management
- Criteria and workflow for library/assay production and transfer
- Knowledge & data transfer

Defined and fully operational





IT infrastructure

- Web portal for library submission
- Chemoinformatics tool to enable library evaluation and selection
- Chemistry management platform (TarosGate) for library progress and logistics tracking
- Honest Data Broker (HDB) for facilitating the confidential evaluation of biological data

Fully operational

Additional advantages






Collective Intelligence EU Lead Factory



integrative 🔅 efpta



Geographic distribution of public target proposals



Status March 31, 2017

Eligible

Submitted (149)

Accepted (85)





ELF: Collaborative Big Data

- 128,204,242 data points
- 42,522,956 primary HTS entries in Screening Result Lists
- 452,655 compounds in the 2017 screening set
- 26,253 compounds selected for Preliminary Hit Lists
- 4246 compounds selected for Revised Hit Lists
- 73 HDB users across Europe








4th Annual Chemistry Learnings & Achievements Meeting

Goals:


- Exchange of the knowledge
- > Integration
- High quality scientific presentations
- Recognition of excellence







> 50 Publications



increative contraction of the second second



A blueprint for public-private partnerships



Nature Reviews Drug Discovery **15**, 221–222 (2016) by Katie Kingwell



The European Lead Factory: A Blueprint for Public–Private Partnerships in Early Drug Discovery

🌠 Anna Karawajczyk; 👤 Kristina M. Orrling?, 🌉 Jon S. B. de Vlieger², 👤 Ton Rijnders² and 🗶 Dimitrios Tzalis:*

¹Taros Chemicals GmbH & Co. KG, Dortmund, Germany ²Lygature, Utrecht, Netherlands

The European Lead Factory (ELF) is a public-private partnership (PPP) that provides researchers in Europe with a unique platform for translation of innovative biology and chemistry into high-quality starting points for drug discovery. It combines an exceptional collection of small molecules, high-throughput screening (HTS) infrastructure, and hit follow-up capabilities to advance research projects from both private companies and publicly funded researchers. By active

Frontiers in Medicine **3**, 75 (2017); Open Access




Euronews BUSINESS PLANET, 2016-12-28 Jan Skriwanek NKS Dimitrios Tzalis ELF






Therapeutic area distribution







Comparison of target distribution




Status March 31, 2017





Progress 2013 - 2017



Powerful drug discovery engine!





Life after ELF...

Investment in spin-out from charity

Virtual biotech company launched to battle Parkinson's

PARKINSON'S^{UK} CHANGE ATTITUDES. FIND A CURE. JOIN US.

08.03.2017 In a world-first type of collaboration, Parkinson's UK and the University of Sheffield have launched a joint venture biotech company, Keapstone Therapeutics. Parkinson's UK has allocated 1 million GBP over the next sixteen months to further develop compounds that boost the internal cellular defence mechanisms against oxidative stress. These compounds were

discovered by IMI's European Lead Factory.

Further development within IMI's ENABLE project



Promising antibiotic programme gets European boost

Innovative Medicines Initiative projects European Lead Factory and ENABLE create pipeline for novel antibiotics from University of Oxford

New spin-out company & investment

European Lead Factory drug-like hit leads to creation of a spin-out

23.11.2016



Dr. Margit Mahlapuu, one of the academic researchers who has benefited from EU Lead Factory screening activities by identifying a drug candidate series for type 2 diabetes, went on to create a spin-out company based on these results. Dr Mahlapuu's group, based at the University of Gothenburg, first... Read more

Advancing science, creating new companies, exploiting IMI project synergies for patient benefit





Testimonials: Public Target Owners



Dr Margit Mahlapuu Univ of Gothenburg

We had already performed a small-scale screen that did not identify a compound with sufficient potency to build on. The synergy in competencies between my lab and the EU Lead Factory has given the project a big push forward.



'Overall, we are **extremely satisfied** with the progress, from **ANTI**assay optimization to post-hit validation. The work done within ELF is really of **high industry-like standard** and **very professional**.'

'It is an initiative that needs to be continued.'




Dr Joost Uitdehaag NTRC

University of Oxford

'Through ELF we now have access to unique and tractable chemotypes. They allowed us to get proof-of-concept in vivo and eventually develop a best-in-class drug candidate.'








The **University of Sheffield** and **Parkinson's UK** have launched a new £1 million virtual biotech company to create new drugs for Parkinson's disease based on a **JECL** new class of compounds that can activate the brain cell defence system.






ELF envisions the engagement of all stakeholders to further increase patient benefit








Interactions













www.europeanleadfactory.eu

Only the official and formally signed contractual documents in relation to the European Lead Factory (Project Agreement, Grant Agreement, Description of Work, and Third Party Access Agreements) have a binding value in relation to the subject matter covered in these slides. Any information contained in these slides is not binding upon the parties and can in no event be used to interpret or complement the formally signed contractual documents referred to above.

